Glenmede Trust’s Pfizer PFE Stock Holding History

Glenmede Trust’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$25.3M	Sell	902,032 -53,129	-6%	-$1.41M	0.12%	140
2025 Q4	$23.8M	Buy	+955,161	New	+$24.1M	0.11%	153
2025 Q1	$21.1M	Sell	834,314 -24,762	-3%	-$648K	0.11%	162
2024 Q4	$22.8M	Sell	859,076 -208,853	-20%	-$5.67M	0.12%	163
2024 Q3	$30.9M	Sell	1,067,929 -28,214	-3%	-$823K	0.15%	134
2024 Q2	$30.7M	Buy	1,096,143 +15,554	+1%	+$428K	0.16%	129
2024 Q1	$30M	Sell	1,080,589 -279,699	-21%	-$7.76M	0.15%	141
2023 Q4	$39.2M	Sell	1,360,288 -235,681	-15%	-$7.12M	0.2%	110
2023 Q3	$52.9M	Sell	1,595,969 -541,022	-25%	-$19.1M	0.3%	84
2023 Q2	$87.2M	Sell	2,136,991 -617	-0%	-$24K	0.49%	47
2023 Q1	$87.2M	Sell	2,137,608 -180,084	-8%	-$7.78M	0.5%	47
2022 Q4	$119M	Buy	2,317,692 +56,043	+2%	+$2.69M	0.7%	27
2022 Q3	$99M	Sell	2,261,649 -417,828	-16%	-$20.3M	0.62%	33
2022 Q2	$140M	Buy	2,679,477 +31,480	+1%	+$1.6M	0.82%	18
2022 Q1	$137M	Buy	2,647,997 +238,858	+10%	+$12.4M	0.67%	26
2021 Q4	$142M	Buy	2,409,139 +39,954	+2%	+$1.98M	0.68%	24
2021 Q3	$102M	Sell	2,369,185 -59,055	-2%	-$2.62M	0.53%	37
2021 Q2	$95.1M	Sell	2,428,240 -273,063	-10%	-$10.6M	0.49%	44
2021 Q1	$97.9M	Sell	2,701,303 -766,954	-22%	-$27.2M	0.53%	41
2020 Q4	$128M	Buy	3,468,257 +175,679	+5%	+$6.44M	0.7%	25
2020 Q3	$115M	Buy	3,292,578 +250,674	+8%	+$8.79M	0.69%	29
2020 Q2	$94.4M	Sell	3,041,904 -512,746	-14%	-$17.4M	0.58%	44
2020 Q1	$132M	Hold	3,554,650	–	–	0.6%	39
2019 Q4	$132M	Buy	3,554,650 +665,654	+23%	+$23.7M	0.6%	39
2019 Q3	$98.5K	Sell	2,888,996 -1,848,631	-39%	-$67.2M	0.45%	52
2019 Q2	$195K	Buy	4,737,627 +572,531	+14%	+$22.7M	0.85%	13
2019 Q1	$168K	Sell	4,165,096 -1,207,588	-22%	-$48.4M	0.76%	18
2018 Q4	$223K	Sell	5,372,684 -63,407	-1%	-$2.63M	1.09%	7
2018 Q3	$227M	Buy	5,436,091 +1,950,313	+56%	+$75.1M	0.91%	10
2018 Q2	$120M	Buy	3,485,778 +177,208	+5%	+$6.06M	0.53%	37
2018 Q1	$114M	Hold	3,308,570	–	–	0.47%	47
2017 Q4	$114M	Buy	3,308,570 +908,012	+38%	+$31M	0.47%	47
2017 Q3	$81.3M	Sell	2,400,558 -1,004,364	-29%	-$32.3M	0.36%	70
2017 Q2	$111M	Hold	3,404,922	–	–	0.53%	36
2017 Q1	$111M	Sell	3,404,922 -55,847	-2%	-$1.76M	0.53%	36
2016 Q4	$107M	Buy	3,460,769 +89,551	+3%	+$2.73M	0.58%	26
2016 Q3	$108M	Sell	3,371,218 -47,450	-1%	-$1.59M	0.61%	27
2016 Q2	$114M	Buy	3,418,668 +310,536	+10%	+$9.91M	0.69%	17
2016 Q1	$87.4M	Buy	3,108,132 +174,582	+6%	+$4.99M	0.57%	30
2015 Q4	$89.8M	Buy	2,933,550 +17,546	+0.6%	+$552K	0.61%	23
2015 Q3	$86.9M	Buy	2,916,004 +239,723	+9%	+$7.69M	0.64%	19
2015 Q2	$85.1M	Sell	2,676,281 -90,285	-3%	-$2.94M	0.61%	22
2015 Q1	$91.3M	Buy	2,766,566 +219,213	+9%	+$6.97M	0.67%	17
2014 Q4	$75.3M	Buy	2,547,353 +64,569	+3%	+$1.85M	0.59%	26
2014 Q3	$69.7M	Buy	2,482,784 +156,297	+7%	+$4.39M	0.61%	27
2014 Q2	$65.5M	Sell	2,326,487 -2,484	-0.1%	-$70.8K	0.59%	32
2014 Q1	$71M	Buy	2,328,971 +16,029	+0.7%	+$478K	0.66%	26
2013 Q4	$67.2M	Buy	2,312,942 +155,110	+7%	+$4.51M	0.69%	26
2013 Q3	$58.8M	Buy	2,157,832 +10,632	+0.5%	+$289K	0.7%	27
2013 Q2	$57.1M	Buy	+2,147,200	New	+$59.3M	0.71%	28

Other funds holding PFE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Glenmede Trust's PFE Position: Q1 2026 in Review

Glenmede Trust reduced its Pfizer (PFE) stake by 5.6% in Q1 2026, selling an estimated $1.41M and leaving 902,032 shares worth $25.3M. The position accounts for 0.12% of the portfolio, ranked #140.

Glenmede Trust first reported a position in PFE in Q2 2013 and has held it in 50 quarters since. The position peaked at $227M in Q3 2018. 2,936 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

Glenmede Trust held 902,032 shares of Pfizer worth $25.3M as of Q1 2026.
Glenmede Trust sold 53,129 Pfizer shares in Q1 2026, an estimated $1.41M.
Pfizer made up 0.12% of Glenmede Trust's portfolio in Q1 2026, its #140 holding.
Glenmede Trust first reported a position in Pfizer in Q2 2013 and has held it in 50 quarters since.
Glenmede Trust's Pfizer position peaked at $227M in Q3 2018.
2,936 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Glenmede Trust's 13F filing for Q1 2026, filed 26 May 2026.